Probiotics, gut microbiota and health

Medecine et Maladies Infectieuses

Volumn 44, Issue 1, 2014, Pages 1-8

  Butel, M J ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Allergy; CIBD; Microbiota; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ABSCESS; ACUTE DIARRHEA; ALLERGIC DISEASE; ANTIMICROBIAL ACTIVITY; BACTEREMIA; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; BIFIDOBACTERIUM; CROHN DISEASE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; DYSBIOSIS; ENDOCARDITIS; FUNGEMIA; GASTROINTESTINAL MUCOSA; HELICOBACTER INFECTION; HUMAN; IMMUNOMODULATION; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS; LYMPHOCYTE ACTIVATION; METABOLIC ACIDOSIS; METAGENOMICS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ULCERATIVE COLITIS;

ALLERGIE; ALLERGY; CIBD; MICI; MICROBIOTA; MICROBIOTE; PROBIOTICS; PROBIOTIQUES;

ADULT; ANIMALS; CLINICAL TRIALS AS TOPIC; CULTURED MILK PRODUCTS; DIABETES MELLITUS, TYPE 2; DIARRHEA; GASTROINTESTINAL TRACT; HEALTH PROMOTION; HELICOBACTER INFECTIONS; HUMANS; HYPERSENSITIVITY; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MICROBIOTA; OBESITY; PROBIOTICS; SPECIES SPECIFICITY;

EID: 84892514212     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.10.002     Document Type: Review

References (66)

1. Anonyme. Report of a joint FAO/WHO Expert Consultation. Health and nutritional properties of probiotics in food includion powder milk with live lactic acid bacteria. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. Cordoba, Argentina, October 2001.
2. Anonyme. Report of a joint FAO/WHO Expert Consultation. Guidelines for the evaluation of probiotics in food. http://www.fda.gov/ohrms/dockets/dockets/95s0316/95s-0316-rpt0282-tab-03-ref-19-joint-faowho-vol219.pdf. London, Canada, April 2002.
3. Martin R., Jimenez E., Heilig H., Fernandez L., Marin M.L., Zoetendal E.G., et al. Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-DGGE and qRTi-PCR. Appl Environ Microbiol 2009, 75:965-969.
4. Maldonado J., Canabate F., Sempere L., Vela F., Sanchez A.R., Narbona E., et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastro-intestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr 2012, 54:55-61.
5. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
6. Round J.L., Mazmanian S.K. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009, 9:313-323.
7. Menard O., Butel M.J., Gaboriau-Routhiau V., Waligora-Dupriet A.J. Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated from infants. Appl Environ Microbiol 2008, 74:660-666.
8. Cannon J.P., Lee T.A., Bolanos J.T., Danziger L.H. Pathogenic relevance of Lactobacillus: a retrospective review of over 200 cases. Eur J Clin Microbiol Infect Dis 2005, 24:31-40.
9. Franz C.M., Huch M., Abriouel H., Holzapfel W., Galvez A. Enterococci as probiotics and their implications in food safety. Int J Food Microbiol 2011, 151:125-140.
10. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008, 46(Suppl 2):S104-S111.
11. Salminen M.K., Tynkkynen S., Rautelin H., Saxelin M., Vaara M., Ruutu P., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002, 35:1155-1160.
12. Lherm T., Monet C., Nougiere B., Soulier M., Larbi D., Le G.C., et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002, 28:797-801.
13. Hennequin C., Kauffmann-Lacroix C., Jobert A., Viard J.P., Ricour C., Jacquemin J.L., et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis 2000, 19:16-20.
14. Connolly E., Abrahamsson T., Bjorksten B. Safety of D(-)-lactic acid producing bacteria in the human infant. J Pediatr Gastroenterol Nutr 2005, 41:489-492.
15. Schjorring S., Krogfelt K.A. Assessment of bacterial antibiotic resistance transfer in the gut. Int J Microbiol 2011; 2011, 2011:3129-3156.
16. Egervarn M., Roos S., Lindmark H. Identification and characterization of antibiotic resistance genes in Lactobacillus reuteri and Lactobacillus plantarum. J Appl Microbiol 2009, 107:1658-1668.
17. Aires J., Doucet-Populaire F., Butel M.J. Tetracycline resistance mediated by tet(W), tet(M), and tet(O) genes of Bifidobacterium isolates from humans. Appl Environ Microbiol 2007, 73:2751-2754.
18. Egervarn M., Lindmark H., Olsson J., Roos S. Transferability of a tetracycline resistance gene from probiotic Lactobacillus reuteri to bacteria in the gastro-intestinal tract of humans. Antonie van Leeuwenhoek 2010, 97:189-200.
19. Jacobsen L., Wilcks A., Hammer K., Huys G., Gevers D., Andersen S.R. Horizontal transfer of tet(M) and erm(B) resistance plasmids from food strains of Lactobacillus plantarum to Enterococcus faecalis JH2-2 in the gastro-intestinal tract of gnotobiotic rats. FEMS Microbiol Ecol 2007, 59:158-166.
20. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev 2010, CD003048.
21. Salari P., Nikfar S., Abdollahi M. A meta-analysis and systematic review on the effect of probiotics in acute diarrhea. Inflamm Allergy Drug Targets 2012, 11:3-14.
22. Bernaola A.G., Bada Mancilla C.A., Carreazo Pariasca N.Y., Rojas Galarza R.A. Probiotics for treating persistent diarrhoea in children. Cochrane Database Syst Rev 2010, CD007401.
23. Szajewska H., Wanke M., Patro B., Meta-analysis: the effects of Lactobacillus rhamnosus GG supplementation for the prevention of healthcare-associated diarrhoea in children. Aliment Pharmacol Ther 2011, 34:1079-1087.
24. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
25. Goldenberg J.Z., Ma S.S., Saxton J.D., Martzen M.R., Vandvik P.O., Thorlund K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013, 5:CD006095.
26. Sha S., Xu B., Wang X., Zhang Y., Wang H., Kong X., et al. The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease. Diagn Microbiol Infect Dis 2013, 75:245-251.
27. Meijer B.J., Dieleman L.A. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011, 45(Suppl.):S139-S144.
28. Butterworth A.D., Thomas A.G., Akobeng A.K. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008, CD006634.
29. Rahimi R., Nikfar S., Rahimi F., Elahi B., Derakhshani S., Vafaie M., et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008, 53:2524-2531.
30. Floch M.H., Walker W.A., Madsen K., Sanders M.E., Macfarlane G.T., Flint H.J., et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011, 45(Suppl.):S168-S171.
31. Mack D.R. Probiotics in inflammatory bowel diseases and associated conditions. Nutrients 2011, 3:245-264.
32. Sokol H., Seksik P., Furet J.P., Firmesse O., Nion-Larmurier I., Beaugerie L., et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 2009, 15:1183-1189.
33. Salonen A., De Vos W.M., Palva A. Gastro-intestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010, 156:3205-3215.
34. Almansa C., Agrawal A., Houghton L.A. Intestinal microbiota, pathophysiology and translation to probiotic use in patients with irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2012, 6:383-398.
35. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012, 367:1626-1635.
36. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Brandt L.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010, 59:325-332.
37. Hoveyda N., Heneghan C., Mahtani K.R., Perera R., Roberts N., Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009, 9:15.
38. McKenzie Y.A., Alder A., Anderson W., Wills A., Goddard L., Gulia P., et al. British Dietetic Association evidence-based guidelines for the dietary management of irritable bowel syndrome in adults. J Hum Nutr Diet 2012, 25:260-274.
39. Okada H., Kuhn C., Feillet H., Bach J.F. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clin Exp Immunol 2010, 160:1-9.
40. Waligora-Dupriet A.J., Butel MJ: Microbiota and allergy: from dysbiosis to probiotics. Allergic diseases-highlights in the clinic, mechanisms and treatment 2012, 413-434. Intech, Rijeka. C. Pereira (Ed.).
41. Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010, 160:295-304.
42. Pelucchi C., Chatenoud L., Turati F., Galeone C., Moja L., Bach J.F., et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology 2012, 23:402-414.
43. Malfertheiner P., Megraud F., O'Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al. Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report. Gut 2012, 61:646-664.
44. Szajewska H., Horvath A., Piwowarczyk A., Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010, 32:1069-1079.
45. Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
46. Qin J., Li Y., Cai Z., Li S., Zhu J., Zhang F., et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490:55-60.
47. Shen J., Obin M.S., Zhao L. The gut microbiota, obesity and insulin resistance. Mol Aspects Med 2013, 34:39-58.
48. Sanz Y., Rastmanesh R., Agostonic C. Understanding the role of gut microbes and probiotics in obesity: how far are we?. Pharmacol Res 2013, 69:144-155.
49. de Vos W.M., Nieuwdorp M. Genomics: A gut prediction. Nature 2013, 498:48-49.
50. Serban E.D. Gastro-intestinal cancers: influence of gut microbiota, probiotics and prebiotics. Cancer Lett 2013.
51. Hao Q., Lu Z., Dong B.R., Huang C.Q., Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2011, CD006895.
52. Williams K., Tang M., Williams K. Probiotics may prevent upper respiratory tract infections, but should we recommend them?. J Paediatr Child Health 2012, 48:942-943.
53. Campeotto F., Waligora-Dupriet A.J., Doucet-Populaire F., Kalach N., Dupont C., Butel M.J. [Establishment of the intestinal microflora in neonates]. Gastroenterol Clin Biol 2007, 31:533-542.
54. Rautava S., Ruuskanen O., Ouwehand A., Salminen S., Isolauri E. The hygiene hypothesis of atopic disease-an extended version. J Pediatr Gastroenterol Nutr 2004, 38:378-388.
55. Laubereau B., Filipiak-Pittroff B., von B.A., Grubl A., Reinhardt D., Wichmann H.E., et al. Caesarean section and gastro-intestinal symptoms, atopic dermatitis, and sensitisation during the first year of life. Arch Dis Child 2004, 89:993-997.
56. Huh S.Y., Rifas-Shiman S.L., Zera C.A., Edwards J.W., Oken E., Weiss S.T., et al. Delivery by caesarean section and risk of obesity in preschool age children: a prospective cohort study. Arch Dis Child 2012.
57. Agosti M., Vegni C., Gangi S., Benedetti V., Marini A. Allergic manifestations in very low-birthweight infants: a 6-year follow-up. Acta Paediatr Suppl 2003, 91:44-47.
58. Schippa S., Conte M.P., Borrelli O., Iebba V., Aleandri M., Seganti L., et al. Dominant genotypes in mucosa-associated Escherichia coli strains from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2009, 15:661-672.
59. Finegold S.M., Molitoris D., Song Y., Liu C., Vaisanen M.L., Bolte E., et al. Gastro-intestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35:S6-S16.
60. Cardwell C.R., Stene L.C., Joner G., Cinek O., Svensson J., Goldacre M.J., et al. Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 2008, 51:726-735.
61. Braegger C., Chmielewska A., Decsi T., Kolacek S., Mihatsch W., Moreno L., et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2011, 52:238-250.
62. Foolad N., Brezinski E.A., Chase E.P., Armstrong A.W. Effect of nutrient supplementation on atopic dermatitis in children: a systematic review of probiotics, prebiotics, formula, and fatty acids. JAMA Dermatol 2013, 149:350-355.
63. Boyle R.J., Bath-Hextall F.J., Leonardi-Bee J., Murrell D.F., Tang M.L. Probiotics for treating eczema. Cochrane Database Syst Rev 2008, CD006135.
64. Luoto R., Kalliomaki M., Laitinen K., Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int J Obes (Lond) 2010, 34:1531-1537.
65. Alfaleh K., Anabrees J., Bassler D., Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, CD005496.
66. Deshpande G.C., Rao S.C., Keil A.D., Patole S.K. Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 2011, 9:92.